RoslinCT to manufacture exagamglogene autotemcel (exa-cel) for Vertex Pharmaceuticals Inc following an extensive development collaboration RoslinCT will manufacture world’s-first CRISPR-based...
Rated “Outperform” with price target of €7.10 Analysts cite $60 million BARDA contract for Crossject’s ZEPIZURE® as validation of platform...
STOCKHOLM, SWEDEN / ACCESSWIRE / November 28, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a...
STOCKHOLM, SWEDEN / ACCESSWIRE / November 28, 2023 / Promore Pharma (STO:PROMO)(FRA:8T0)July to SeptemberNet sales amounted to MSEK 0 (0)Net...
New offering provides an all-in-one AI platform optimized for mammography, that seamlessly integrates artificial intelligence (AI) applications from iCAD to...
SAN MATEO, Calif.--(BUSINESS WIRE)--Model N, Inc. (NYSE: MODN), the leader in revenue optimization and compliance today announced that Model N...
The ICONIC program now includes four Phase 3 studies evaluating JNJ-2113; Co-primary endpoints for all four studies are PASI-90 and/or...
ZURICH, SWITZERLAND / ACCESSWIRE / November 27, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss...
Phase 1 ex-US trial achieved primary objective of predictable pharmacokinetic profiling with favorable safety and tolerabilityCompany expects to engage FDA...
TORONTO, ON / ACCESSWIRE / November 27, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical...
Clearmind Medicine CEO, Dr. Adi Zuloff-Shani, and MAPS founder and psychedelic sector pioneer, Rick Doblin, will discuss the growing and...
MitoCareX Bio has met its second milestone as part of its joint venture agreement with the Company TEL AVIV, Israel,...
Clinical development plan leveraging 505(b)(2) regulatory pathway Initiation of Phase 2a biomarker study on track to start before year end...
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetesNew...
GIMOTI now holds four listed patents with coverage through 2029SOLANA BEACH, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma,...
-Partnership Expands TOMI’s Market in Food, Agriculture, and Cannabis Industries -FREDERICK, Md., Nov. 27, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental...
Resubmission of the ONS-5010 BLA on track for the end of calendar year 2024, pending final agreement on a clinical...
STOUGHTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today...
Mr. Schachle Brings Over 30 Years of Experience in Biotech and Pharma with Expertise Across Multiple Functional Areas Including Corporate...
Oral brepocitinib failed to meet its primary endpoint of Systemic Lupus Erythematosus Responder Index (SRI-4) change of 4 at Week...